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STUDY QUESTION: Over a time period of 3 years, which order of expectant management (EM), IUI with ovarian stimulation (IUI-OS)
and IVF is the most cost-effective for couples with unexplained subfertility with the female age below 38 years?
SUMMARY ANSWER: If a live birth is considered worth e32 000 or less, 2 years of EM followed by IVF was the most cost-effective,
whereas above e32 000 this was 1 year of EM, 1 year of IUI-OS and then 1 year of IVF.
WHAT IS KNOWN ALREADY: IUI-OS and IVF are commonly used fertility treatments for unexplained subfertility although many cou-
ples can conceive naturally, as no identifiable barrier to conception could be found by definition. Few countries have guidelines on when to
proceed with medically assisted reproduction (MAR), mostly based on the expected probability of live birth after treatment, but there is a
lack of evidence to support the strategies proposed by these guidelines. The increased uptake of IUI-OS and IVF over the past decades
and costs related to reimbursement of these treatments are pressing concerns to health service providers. For MAR to remain affordable,
sustainable and a responsible use of public funds, guidance is needed on the cost-effectiveness of treatment strategies for unexplained sub-
fertility, including EM.
STUDY DESIGN, SIZE, DURATION: We developed a decision analytic Markov model that follows couples with unexplained subfertil-
ity of which the woman is under 38 years of age for a time period of 3 years from completion of the fertility workup onwards. We divided
the time axis of 3 years into three separate periods, each comprising 1 year. The model was based on contemporary evidence, most nota-
bly the dynamic prediction model for natural conception, which was combined with MAR treatment effects from a network meta-analysis
on randomized controlled trials. We changed the order of options for managing unexplained subfertility for the 1 year periods to yield five
different treatment policies in total: IVF-EM-EM (immediate IVF), EM-IVF-EM (delayed IVF), EM-EM-IVF (postponed IVF), IUIOS-IVF-EM
(immediate IUI-OS) and EM-IUIOS-IVF (delayed IUI-OS).
PARTICIPANTS/MATERIALS, SETTING, METHODS: The main outcomes per policy over the 3-year period were the probability
of live birth, the average treatment and delivery costs, the probability of multiple pregnancy, the incremental cost-effectiveness ratio (ICER)
and finally, which policy yields the highest net benefit in which costs for a policy were deducted from the health effects, i.e. live births
gained. We chose the Dutch societal perspective, but the model can be easily modified for other locations or other perspectives. The
probability of live birth after EM was taken from the dynamic prediction model for natural conception and updated for Years 2 and 3.
The relative effects of IUI-OS and IVF in terms of odds ratios, taken from the network meta-analysis, were applied to the probability
of live birth after EM. We applied standard discounting procedures for economic analyses for Years 2 and 3. The uncertainty around
effectiveness, costs and other parameters was assessed by probabilistic sensitivity analysis in which we drew values from distributions and
repeated this procedure 20 000 times. In addition, we changed model assumptions to assess their influence on our results.
VC The Author(s) 2020. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
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MAIN RESULTS AND THE ROLE OF CHANCE: From IVF-EM-EM to EM-IUIOS-IVF, the probability of live birth varied from approxi-
mately 54–64% and the average costs from approximately e4000 to e9000. The policies IVF-EM-EM and EM-IVF-EM were dominated by
EM-EM-IVF as the latter yielded a higher cumulative probability of live birth at a lower cost. The policy IUIOS-IVF-EM was dominated by
EM-IUIOS-IVF as the latter yielded a higher cumulative probability of live birth at a lower cost. After removal of policies that were domi-
nated, the ICER for EM-IUIOS-IVF was approximately e31 000 compared to EM-EM-IVF. The range of ICER values between the lowest
25% and highest 75% of simulation replications was broad. The net benefit curve showed that when we assume a live birth to be worth
approximately e20 000 or less, the policy EM-EM-IVF had the highest probability to achieve the highest net benefit. Between e20 000 and
e50 000 monetary value per live birth, it was uncertain whether EM-EM-IVF was better than EM-IUIOS-IVF, with the turning point of
e32 000. When we assume a monetary value per live birth over e50 000, the policy with the highest probability to achieve the highest net
benefit was EM-IUIOS-IVF. Results for subgroups with different baseline prognoses showed the same policies dominated and the same
two policies that were the most likely to achieve the highest net benefit but at different threshold values for the assumed monetary value
per live birth.
LIMITATIONS, REASONS FOR CAUTION: Our model focused on population level and was thus based on average costs for the av-
erage number of cycles conducted. We also based the model on a number of key assumptions. We changed model assumptions to assess
the influence of these assumptions on our results. The change in relative effectiveness of IVF over time was found to be highly influential
on results and their interpretation.
WIDER IMPLICATIONS OF THE FINDINGS: EM-EM-IVF and EM-IUIOS-IVF followed by IVF were the most cost-effective policies.
The choice depends on the monetary value assigned to a live birth. The results of our study can be used in discussions between clinicians,
couples and policy makers to decide on a sustainable treatment protocol based on the probability of live birth, the costs and the limitations
of MAR treatment.
STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the ZonMw Doelmatigheidsonderzoek (80-85200-98-
91072). The funder had no role in the design, conduct or reporting of this work. B.W.M. is supported by a NHMRC Practitioner
Fellowship (GNT1082548). B.W.M. reports consultancy for ObsEva, Merck KGaA and Guerbet and travel and research support from
ObsEva, Merck and Guerbet.
TRIAL REGISTRATION NUMBER: N/A.
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Introduction
Medically assisted reproduction (MAR), i.e. IUI with ovarian stimu-
lation (IUI-OS) and IVF, is commonly used to treat couples with
unexplained subfertility (Calhaz-Jorge et al., 2017). Only a few
countries have a national guideline for clinical management of cou-
ples with unexplained subfertility. For example, in the UK National
Health Service (NHS), couples with unexplained subfertility of
which the woman is under 40 years of age are eligible for up to a
maximum of three reimbursed IVF cycles after 2 years of trying to
conceive (NICE, 2013). In the Netherlands, unexplained subfertile
couples comprising women below 38 years of age who have a pre-
dicted probability to conceive naturally of <30% over the following
year, as estimated by the Hunault model, are eligible for up to six
reimbursed cycles of IUI-OS and, if unsuccessful, three reimbursed
IVF cycles thereafter (Hunault et al., 2004; van der Steeg et al.,
2007; NVOG, 2010).
Both of these approaches are meant to avoid overtreatment with
MAR, as many of these couples may still conceive naturally and do not
necessarily require any treatment (Kersten et al., 2015). Not only are
IUI-OS and IVF expensive treatments, but IUI-OS leads to a consider-
ably higher probability of multiple pregnancy, and IVF with single em-
bryo transfer is still an invasive and stressful procedure (van den
Boogaard et al., 2011). Postponing treatment saves the patient an inva-
sive procedure and avoids unnecessary costs for couples who might
have conceived naturally.
Because couples with better prognoses conceive before couples
with poorer prognoses, this leads to a selection over time in which
eventually a subgroup with a particularly low prognosis remains (van
Eekelen et al., 2017a). This low prognosis group might benefit from
MAR treatment (van Eekelen et al., 2017b). In times when health care
costs are increasing and becoming a larger relative expenditure for
governments with health service providers, this is a crucial concept
for evidence-based decision-making (OECD, 2013). When it comes to
unexplained subfertility, the question is thus not who to treat, but
when to treat with IUI-OS and when to treat with IVF.
The current body of evidence on this is inconclusive: we previously
found that the prognosis of natural conception determines the relative
and absolute benefit of IUI-OS, which suggests that expectant manage-
ment (EM) is the best option until so much selection has occurred
that the prognosis crosses below a certain threshold (van Eekelen
et al., 2019a). In contrast, it is also known that the probability of live
birth after IVF declines rapidly above a female age of 35 years, provid-
ing an important argument to limit the period of EM that is advised
(McLernon et al., 2016; van Eekelen et al., 2017b; van Eekelen et al.,
2019a,b).
If we consider costs and patient harm, it is better to delay treat-
ment, especially if this does not substantially change the probability of
live birth over a fixed time period. A cost-effectiveness study com-
pared IVF-EM-EM (immediate IVF) to EM-IVF-EM (delayed IVF) and
found that the probabilities of live birth over a 2-year period were sim-
ilar, but the authors used observational data and did not consider IUI-
























































































OS as an intermediate option as unexplained subfertility was not the
main focus of the study (Eijkemans et al., 2017). More evidence is nec-
essary on this topic to decide on sustainable, evidence-based treat-
ment protocols for unexplained subfertility that best utilize public
funds.
The aim of the present study is to assess the cost-effectiveness of
policies regarding different ordering of EM, IUI-OS and IVF for couples




To answer the research question we did not use patient data, but in-
stead combined evidence from contemporary sources to develop a
statistical model commonly referred to as a decision analytic model
(Briggs et al., 2006). We chose a population-level (average) model
based on probabilities known as a Markov model. Since our model
does not contain many ‘intermediate’ states, we show this as a deci-
sion tree. The R programming code used to run the model is available
online (Supplementary Data 1 and 2) as well as Supplementary Data
3, which includes all model parameters such that other researchers
can readily implement the model in their own country or setting in
which parameters such as costs might differ.
Our health outcome of interest is the cumulative probability of live
birth as this is the outcome that matters most to patients and quality-
adjusted life years are poorly defined for this population (Barnhart,
2014; Eijkemans et al., 2017).
The three options for treatment of couples with unexplained
subfertility are EM, IUI-OS and IVF. EM is defined as no intervention
other than the advice to continue trying. IUI-OS using clomiphene
citrate, as clomiphene citrate was shown to lead to similar ongoing
pregnancy rates as gonadotrophins, whilst clomiphene citrate is less
expensive and less invasive for patients to use (Danhof et al.,
2018).
We chose a time window of 3 years as a treatment decision gener-
ally has to (first) be made within 3 years after the diagnosis and, in ad-
dition, to allow sufficient time for couples to undergo both IUI-OS and
IVF, even after postponing treatment for 1 year. We chose (calendar)
time instead of cycles since this aligns with the measures of relative ef-
fectiveness in the network meta-analysis and since one cycle of EM
does not take the same amount of time as one cycle of IVF, which
hampers comparisons. We divided these 3 years into three separate
periods, each comprising 1 year. We then reordered the three options
to be offered over 1-year periods to constitute five policies that are
shown in Table I. For instance, couples might start with IVF straight
away (immediate IVF, order IVF-EM-EM), or opt for the Dutch stan-
dard for couples with a good prognosis of natural conception by delay-
ing IUI-OS by 1 year (delayed IUI-OS, order EM-IUIOS-IVF). After
3 years, we assumed that treatment is finished for the vast majority of
couples and that the years of EM thereafter are similar for all policies.
We assumed most couples would finish IUI-OS and/or IVF within 1
year, which might differ between countries based on reimbursement
or availability. Options with multiple years of treatment (e.g. IVF-IVF-
EM) were considered unrealistic as policies reflect population-level
guidelines and very few couples receive more than two cycles of IVF
or more than four cycles of IUI-OS, which are most often done within
the same year (Custers et al., 2007; McLernon et al., 2016; Eijkemans
et al., 2017; van Eekelen et al., 2019a,b). The option without treat-
ment, i.e. EM-EM-EM was considered unethical and unfeasible given
the current guidelines (NVOG, 2010).
Population
As the question concerns couples who are in a position to postpone
treatment, we chose the population of interest to be couples with
unexplained subfertility who present at a fertility clinic and where the
woman is 38 years old or younger. We defined subfertility as not con-
ceiving within 1 year of trying. Unexplained subfertility was defined as
couples with no major causes explaining the fertility problem, regular
menstrual cycles of length between 23 and 35 days, at least one patent
fallopian tube and semen analyses with a total motile sperm count of
>1  106 (van Eekelen et al., 2017a). We chose 38 years as the age
limit for women as for couples in which the woman over 38 years of
age, the treatment choice is complicated by the rapid decline in the
probability of live birth after IVF and after EM as female age increases,
such that IVF-EM-EM might be preferred (McLernon et al., 2016;
van Eekelen et al., 2019b).
Perspective
We chose the health economic perspective of society as reimburse-
ment in the Netherlands is based on public funds, i.e. taxpayer money.
Work absenteeism was considered a loss of productivity to society.
The model can be easily modified for other perspectives or other
locations.
Primary data sources
Probability of live birth after EM.
As the baseline probability of live birth after EM in the model, we
chose to use our dynamic prediction model for natural conception
(van Eekelen et al., 2017a). This prediction model has been externally
validated in Scottish data and can be used to not only predict the
probability of natural conception after completion of the fertility
workup that leads to ongoing pregnancy, but also to update predic-
tions when couples return to the clinic later after a period of EM (van
Eekelen et al., 2018). This is a crucial property of the decision analytic
model, as it covers 3 years in total and two moments at which the sit-
uation is re-evaluated. The outcome of the dynamic prediction model
was natural conception leading to ongoing pregnancy, but the outcome
of interest is live birth. To estimate the probability of live birth after
natural conception, we multiplied the probability of ongoing pregnancy
from the dynamic prediction model with a probability of continuing to
a live birth (Arce et al., 2005; Braakhekke et al., 2014). We refer to
that as live birth from now on. The average probability of live birth af-
ter natural conception plugged into the economic model was approxi-
mately 26% over the first year and was derived from the cohort used
in that same study for couples in which the woman was below 38 years
of age (van Eekelen et al., 2017a). The average female age in this co-
hort was 31.7 years. The probability of live birth of 26% in the first
year decreased to 15% in Year 2 and to 10% in Year 3. Over the

































































..period of 3 years, the cumulative probability of live birth after natural
conception was 43%.
Probability of live birth after IUI-OS and IVF.
For the probability of live birth after treatment, we applied relative
effects in terms of odds ratios from a recent network meta-analysis on
unexplained subfertile couples to the aforementioned probability of
live birth after EM (Wang et al., 2019). The study found an odds ratio
after IUI-OS of 1.61 (95% CI 0.88–2.94) and after IVF of 1.88 (95% CI
0.81–4.38, only indirect evidence), both compared to EM. IVF refers
to a weighted average of IVF and ICSI as the authors of the network
meta-analysis did not distinguish between IVF and ICSI since there is
no indication for ICSI in unexplained subfertility (Wang et al., 2019).
In previous research, we found that the odds ratio of both IUI-OS
and IVF increased over time, because the probability of live birth after
EM decreases more rapidly than the probability of live birth after IUI-
OS or IVF. The increase in odds ratio was estimated as 1 point per
year for both IUI-OS (Supplementary Data 4). We incorporated this
increase of the odds ratio in our model.
Probability of multiple pregnancy.
We expected a probability of multiple pregnancy after EM of 1%
(Eijkemans et al., 2017; van Eekelen et al., 2017a), after IUI-OS of 6%
(Custers et al., 2007) and after IVF of 3.3% (NVOG, 2018).
Costs
Considered costs were from a health care perspective (procedures re-
garding treatment, medication, delivery of multiple pregnancy) and so-
cietal (work absenteeism). Costs from the health care perspective
were obtained from an expert panel on cost-effectiveness from the
Dutch consortium for Research in Women’s Health consisting of
gynaecologists, an economist and a methodologist. This group col-
lected the total medical costs per resource unit from two university
hospitals and one general hospital. These costs were averaged and
then used to determine the average costs of one full year of IUI-OS
and the average costs of one full year of IVF. Details are reported in
Supplementary Data 3.
Direct medical costs of one cycle of IUI-OS were estimated at e321
(including ovarian stimulation, sonography, semen sample processing,
etc.) and for one cycle of IVF were estimated at e1365 (including ovar-
ian stimulation, sonography, oocyte collection, possible complications
during oocyte collection, embryo culture, embryo transfer, etc.). The
costs of a freeze/thaw attempt were estimated at e350 (including so-
nography and embryo transfer).
Indirect costs, i.e. unrelated to medical procedures were due to ab-
sence from work, estimated at e263 for one full day for a woman and
e316 for one full day for a man (Hakkaart-van Roijen et al., 2016).
Total costs due to absence from work were estimated at e726 per
IUI-OS cycle and e2294 per IVF cycle, the difference mostly being due
to oocyte collection and subsequent rest in IVF.
Most cost data were from 2013 or 2014, so we applied the inflation
factor reported by the Dutch government to update costs to 2018
(CBS, 2020).
The number of cycles conducted in clinical practice is crucial to in-
form the expected average costs. The average number of IUI-OS
cycles received within 1 year, including cancellations and couples that
successfully conceived leading to live birth, was estimated at 4
(Custers et al., 2007; van Eekelen et al., 2019a). The average number
of IVF cycles received was estimated at 1.5 and every cycle was esti-
mated to include one freeze/thaw attempt (Eijkemans et al., 2017; van
Eekelen et al., 2019b).
The incremental cost of delivery in case of a multiple pregnancy was
estimated at e13 312 and was defined as the costs of a multiple preg-
nancy delivery minus the cost of a singleton delivery, as the latter
applies to all deliveries (Lukassen et al., 2004). Other costs related to
pregnancy and delivery were not considered in the model as they
were assumed to be a result of a ‘successful’ treatment rather than
relevant to the treatment decision.
Combining direct medical costs, indirect costs and the inflation fac-
tor, the total average costs of 1 year of IUI-OS comprising four cycles
were estimated at e4528. Four IUI-OS cycles were chosen because
when the protocol is to have up to six cycles, the number of cycles
conducted will be lower due to pregnancies and drop-out (Custers
et al., 2007). Total average costs of 1 year of IVF comprising 1.5 cycles
and subsequent freeze/thaw attempts were estimated at e6595: 1.5
IVF cycles were chosen because when the protocol is to have up to
three cycles, the number of cycles conducted will be lower due to
pregnancies and drop-out (van Eekelen et al., 2019b).
Cost-effectiveness analyses
Model structure.
The decision analytic model is shown as a decision tree in Fig. 1.
Following clinical practice, the couples enter the model after at least 1
year of trying to conceive naturally and diagnosis at a fertility clinic.
............................................................................................................................................................................................................................
Table I The five possible treatment policies for unexplained infertility based on the ordering of EM, IUI-OS and IVF.
Policy Explanation Year 1 Year 2 Year 3
IVF-EM-EM Immediately start with IVF and skip IUI-OS IVF EM EM
EM-IVF-EM Delay IVF for 1 year and skip IUI-OS EM IVF EM
EM-EM-IVF Postpone IVF for 2 years and skip IUI-OS EM EM IVF
IUIOS-IVF-EM Immediately start IUI-OS, then continue with IVF if unsuccessful IUI-OS IVF EM
EM-IUIOS-IVF Delay IUI-OS for 1 year, then continue with IVF if unsuccessful EM IUI-OS IVF
EM, expectant management; EM-EM-IVF, postponed IVF; EM-IUIOS-IVF, delayed IUI-OS; EM-IVF-EM, delayed IVF; IUI-OS, IUI-ovarian stimulation; IUIOS-IVF-EM, immediate IUI-OS;
IVF-EM-EM, immediate IVF; OS, ovarian stimulation.
























































































Depending on the policy, the couples have a probability of achieving a
live birth in each year, which can be singleton or multiple. Couples
who achieve a live birth are not considered further. For instance, in
Fig. 1 we show the policy EM-IUI-IVF, which means that couples who
achieved live birth in year 1 after EM did not incur any treatment
costs. No other health consequences are considered apart from the
probability of having a live birth. Results of the model are cumulative
over the full-time window of 3 years.
An example calculation and its explanation are provided in the
Supplementary Data 4.
All parameters used, their distribution and the sources of evidence
are reported in Table II and are reported in more detail in
Supplementary Data 3.
Discounting and uncertainty.
The main outputs from the model were the cumulative probability of
live birth, the average costs and the cumulative probability of multiple
pregnancy.
We applied standard discounting procedures for economic analyses
for Years 2 and 3, a mechanism which reflects that it is desirable that
costs are made later but undesirable that health outcomes, i.e. live
birth are gained later (Briggs et al., 2006). The Dutch government
advises discounting rates of 4% per year for costs and 1.5% per year
for health outcomes, i.e. live birth (Zorginstituut Nederland, 2016).
The uncertainty around effectiveness, costs and other parameters was
assessed by probabilistic sensitivity analysis in which we drew values
from distributions and repeated this procedure 20 000 times.
Reporting results for cost-effectiveness
The main cost-effectiveness results were the incremental cost-
effectiveness ratios (ICERs) and the probability that a certain policy
was most likely to yield the highest net benefit.
The ICER is the increase in average cost divided by the increase in
the probability of live birth for a more effective but also more expen-
sive policy (Briggs et al., 2006). We opted for a step-wise approach to
compare ICERs for increasingly more effective but also more expen-
sive policies (Briggs et al., 2006).
For net benefit, we expressed how much monetary gain there is to
be had for each policy by expressing the health outcome of live birth
in terms of a monetary value. We achieved this by multiplying the cu-
mulative probability of live birth by a monetary value between e1 and
e100 000 and deducting the costs of that policy (Briggs et al., 2006).
The result is the monetary benefit of that policy in terms of health
gained minus the costs. For each simulation replication, we determined
which of the five policies yielded the highest net benefit for the range
of possible monetary values, then calculated the proportion of simula-
tion replications in which each policy was the best. The results are
thus interpretable as the probability that a policy yields the highest net
benefit, given that we assume live birth to be worth a certain mone-
tary value. This curve is more informative than just the ICER as it takes
into account all possible monetary values per live birth that vary from
perspective or setting, the uncertainty around all parameters and it
includes all policies simultaneously without the need for arbitrarily
choosing a reference policy.
Sensitivity analyses
In addition to the primary analysis, we changed model assumptions to
assess their influence on our results. First, to see the difference with
the population average, we looked at the cost-effectiveness within sub-
populations with a probability of live birth of 10%, 20%, 30% or 40%
over the first year after the fertility workup. These subpopulations can
be seen as couples in which the female age varies (increased age 10%
vs younger age 40%).
Second, we changed the time window from 3 years to 1.5 years,
with each period comprising 6 months, to show what would occur if
the treatment decision were made earlier.
Third, we removed indirect costs due to absence of work from the
model, yielding a model with only direct medical costs which can be
viewed as a health service provider perspective or insurer perspective.
Fourth, we fixed the odds ratio of IVF over time, instead of increas-
ing the odds ratio by 1 point per year, to assess the influence of this
assumption.
Fifth, we used probability distributions for the probability of multiple
pregnancy instead of assuming fixed values of 1% for EM, 6% for IUI-
OS and 3.3% for IVF to see if this changed results.
Results
The main results are displayed in Table III. From the policy with the
lowest probability of live birth IVF-EM-EM to the highest EM-IUIOS-
IVF, the probability of live birth varied from approximately 54–64%,
the average costs from approximately e4000 to e9000 and the proba-
bility of multiple pregnancy from 1.4% to 3.4%. The policies IVF-EM-
EM and EM-IVF-EM were dominated by EM-EM-IVF (postponed IVF)
as the latter yielded a higher cumulative probability of live birth at a
lower cost. The policy IUIOS-IVF-EM (immediate IUI-OS) was domi-
nated by EM-IUIOS-IVF as the latter yielded a higher cumulative
Figure 1. The decision analytic model, shown as a decision
tree, in this example for the policy EM-IUI-OS-IVF. The pol-
icy of delayed IUI-ovarian stimulation with expectant management
(EM-IUI-OS-IVF) is shown. Only couples with unexplained subfertility
that do not achieve live birth in Year 1 continue to Year 2 and incur
costs and the same goes for couples in Years 2 and 3. In addition,
couples who have a multiple pregnancy incur costs. No health out-
comes other than live birth were considered. Shown probabilities
are only examples. Other policies were similar except for the treat-
ment offered per year.












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































.. probability of live birth at a lower cost. After removal of policies that
were dominated, the comparison was made between the two remain-
ing policies: the ICER for EM-IUIOS-IVF was approximately e31 000
compared to EM-EM-IVF. The range of ICER values between the low-
est 25% and highest 75% of simulation replications was broad.
The net benefit curves for a range of monetary value per live birth
are shown in Fig. 2.
The curve showed that when we assume a live birth to be worth
approximately e20 000 or less, the policy EM-EM-IVF had a probability
over 90% to achieve the highest net benefit. Between e20 000 and
e50 000 monetary value per live birth, it was uncertain whether EM-
EM-IVF was better than EM-IUIOS-IVF (delayed IUI), with the turning
point at e32 000. When we assume a monetary value per live birth
over e50 000, the policy EM-IUIOS-IVF had a probability over 90% to
achieve the highest net benefit.
Sensitivity analyses
ICERs from the sensitivity analyses choosing a prognosis subgroup
ranging from a probability of live birth ranging 10–40% over the year
after the fertility workup are shown in Supplementary Tables SI, SII,
SIII and SIV. The cumulative probability of live birth over 3 years
ranged from 25% (IVF-EM-EM in the 10% prognosis group) to 81%
(EM-IUIOS-IVF in the 40% prognosis group). All four analyses showed
the same dominance pattern as the primary analysis, with EM-EM-IVF
and EM-IUIOS-IVF being the remaining policies to compare. The
ICERs for EM-IUIOS-IVF compared to EM-EM-IVF for the four progno-
ses groups were e59 000, e36 000, e30 000 and e28 000,
respectively.
The net benefit curves for the prognosis subgroups ranging from
10% to 40% are shown in Supplementary Figs S1, S2, S3 and S4.
Similar to the primary analysis on the overall population, EM-EM-IVF
was the most likely to yield the highest benefit up to e60 000 (10%
prognosis) decreasing to e29 000 (40% prognosis), after which EM-






























































































































































































































































































































































































































































































































































































































Figure 2. Net benefit curves for all five policies. EM-EM-IVF,
postponed IVF; EM-IUIOS-IVF, delayed IUI-OS; EM-IVF-EM, delayed
IVF; IUIOS-IVF-EM, immediate IUI-OS; IVF-EM-EM, immediate IVF.
























































































The results of the analysis with a time window of 18 months com-
prising of three 6-month periods are reported in Supplementary Table
SV and Fig. S5. The same dominance pattern as in the primary analysis
was found and the ICER of EM-IUIOS-IVF compared to EM-EM-IVF
was e18 000.
The results of the analysis in which we removed indirect costs, i.e.
absence of work are reported in Supplementary Table SVI and Fig. S6.
Average costs were considerably lower compared to the primary
analysis and ICERs were lower. The same dominance pattern as in the
primary analysis was found and the ICER of EM-IUIOS-IVF compared
to EM-EM-IVF was e9400.
The results of the analysis in which we assumed the relative treat-
ment effects remained stable over time are reported in Supplementary
Table SVII and Fig. S7. The policies in which treatment was started
earlier now showed an increased cumulative probability of live birth
compared to policies in which treatment was postponed. The policy
EM-IUIOS-IVF was now dominated by IVF-EM-EM, yielding a higher
cumulative probability of live birth at a lower cost. The net benefit
curve was not straightforward for this policy with multiple policies
competing. Up to a value of e44 000 per live birth, EM-EM-IVF was
the most likely to yield the highest net benefit, after which none of the
other policies reached a probability over 50% to yield the highest net
benefit and thus results remained inconclusive.
Applying a distribution for the chance of multiple pregnancy had a
negligible influence on the results (data not shown).
Discussion
We found that if stakeholders or society as a whole consider a live
birth to be worth a relatively low monetary value (e20 000 or less),
the least expensive but most cost-effective policy in terms of net bene-
fit was 2 years of EM followed by IVF. If a live birth is considered to
be worth more than e50 000, the most cost-effective policy in terms
of net benefit was 1 year of EM followed by 1 year of IUI-OS and
then 1 year of IVF. Between these values, with a turning point at
e32 000, it was uncertain which policy yielded the highest net benefit.
If indirect costs are ignored, this threshold monetary value was
much lower at e9500. If the relative effect of IUI-OS and IVF would
not change over time, policies in which treatment is started earlier
yield a higher cumulative probability of live birth over 3 years.
Strengths of this study include the combination of evidence from
contemporary sources, presentation of model results in several ways
to showcase different perspectives and the honest reflection of uncer-
tainty by using distributions in a probabilistic sensitivity analysis in which
the model simulation was repeated 20 000 times.
The quality of the present study is nonetheless limited by the cur-
rent evidence regarding the effectiveness of MAR for unexplained sub-
fertility, most notably the MAR treatment effects in terms of odds
ratios compared to EM, the uncertainty around these odds ratios and
whether these can be expected to be similar at later treatment start
(Wang et al., 2019). The effect of IVF compared to EM as estimated
in the network meta-analysis was based on indirect comparisons only.
Previous work suggested that as the prognosis of natural conception
decreases over time due to selection, but the absolute chance after
MAR decreases much slower, the relative effect expressed as hazard
ratios or odds ratios tends to increase over time (van Eekelen et al.,
2019b). Please see the Supplementary Data 4 for more details. We in-
corporated this in our analysis, and removed this mechanism in a sen-
sitivity analysis, which was highly influential on results and their
interpretation on the influence of postponing treatment on the cumu-
lative probability of live birth, i.e. how many livebirths would be ‘lost’.
As there is no clear evidence on this matter, we were unable to ad-
dress this further. The same can be said on finding subgroups for
which MAR is more, or less, effective than the average odds ratio
from the network meta-analysis, which could lead to different results
in the sensitivity analyses on prognosis groups. Another call of evi-
dence of MAR treatment effects for unexplained subfertility seems
warranted to improve precision of the decision analytic model, im-
prove our knowledge on cost-effectiveness and ultimately help make a
treatment decision for couples with unexplained subfertility.
Our model, although based on contemporary evidence, was not
free of assumptions and was based on calendar time to align with the
network meta-analysis and to make a fair comparison for an average
number of cycles conducted within the 1-year periods. We acknowl-
edge that this was an important choice but wish to emphasize that
other options, such as cycle-based models, come with even more cru-
cial assumptions. We incorporated uncertainty around important
parameters, such as relative treatment effects and costs, by drawing
from distributions rather than choosing one fixed value.
Our results reaffirm the logic behind guidelines for subfertility from
the UK and the Netherlands in which IVF is reimbursed using public
funds but not immediately offered after completion of the fertility
workup. Despite some couples receiving both IUI-OS and IVF, and
thus stacking costs, the EM-IUIOS-IVF policy was comparable to IVF-
EM-EM in terms of average costs, i.e. the policy in which all couples
start with IVF, but in the EM-IUIOS-IVF policy not all couples will re-
ceive the most invasive procedure IVF and the cumulative probability
of live birth was higher. For couples under 38 years of age who can
still pursue EM for longer, it might be worthwhile to wait another year
or two before starting IVF to avoid unnecessary invasive and expensive
treatment. After 2 years of waiting, the subgroup that remains is
expected to benefit considerably from IVF treatment.
EM may be perceived as ‘pointless’ by unexplained subfertile cou-
ples, which can also decrease their quality of life (van den Boogaard
et al., 2011). However, counselling by a clinician and providing realistic
treatment success probabilities can help couples have realistic expecta-
tions and improve their satisfaction with the decision-making process.
The results of our study can be used in discussions between clini-
cians, couples and policy makers to decide on a sustainable treatment
protocol based on the probability of live birth, the costs and the limita-
tions of MAR treatment. Our model used contemporary evidence and
all necessary programming code is provided such that it is easy to ap-
ply in other countries where, for instance, costs might differ.
Conclusion
EM-EM-IVF and EM-IUIOS-IVF followed by IVF were the most cost-
effective policies. The choice depends on how much a live birth is con-
sidered to be worth in terms of monetary value.

























































































Supplementary data are available at Human Reproduction online.
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